Glaukos Sets IPO Pricing Range, Launches IPO

Laguna Hills-based Glaukos Corporation, which is developing medical devices for treating glaucoma, said this morning that it has formally launched its IPO, and is now looking to sell 5,358,000 shares of its common stock at between $13.00 and $15.00 per share. Glaukos said it has applied to list on the New York Stock Exchange as GKOS. Glaukos had filed for its IPO in May, but by setting a pricing range, is one step closer to the market. The IPO is being underwritten by J.P. Morgan, BofA Merrill Lynch, and Goldman, Sachs & Co., along with William Blair and Cantor Fitzgerald.